Genmab A/S (NASDAQ:GMAB) Shares Bought by Creative Planning

Creative Planning boosted its position in Genmab A/S (NASDAQ:GMAB - Free Report) by 136.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 47,422 shares of the company's stock after purchasing an additional 27,353 shares during the period. Creative Planning's holdings in Genmab A/S were worth $1,156,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also added to or reduced their stakes in the company. Ritholtz Wealth Management bought a new stake in Genmab A/S in the third quarter worth about $314,000. Sanctuary Advisors LLC bought a new stake in shares of Genmab A/S during the second quarter valued at approximately $1,354,000. Point72 Asset Management L.P. bought a new stake in shares of Genmab A/S during the second quarter valued at approximately $457,000. Cubist Systematic Strategies LLC raised its stake in shares of Genmab A/S by 109.7% during the second quarter. Cubist Systematic Strategies LLC now owns 278,541 shares of the company's stock valued at $7,000,000 after acquiring an additional 145,689 shares in the last quarter. Finally, Benjamin F. Edwards & Company Inc. raised its stake in shares of Genmab A/S by 7.1% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 7,227 shares of the company's stock valued at $182,000 after acquiring an additional 478 shares in the last quarter. Institutional investors own 7.07% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on GMAB shares. Truist Financial decreased their price target on shares of Genmab A/S from $53.00 to $50.00 and set a "buy" rating for the company in a research note on Monday, September 9th. HC Wainwright reaffirmed a "buy" rating and set a $50.00 price target on shares of Genmab A/S in a research note on Wednesday, October 16th. Royal Bank of Canada raised shares of Genmab A/S from a "sector perform" rating to an "outperform" rating in a report on Monday, July 15th. JPMorgan Chase & Co. reissued a "neutral" rating on shares of Genmab A/S in a report on Tuesday, August 20th. Finally, Morgan Stanley reissued an "equal weight" rating and set a $31.00 price objective on shares of Genmab A/S in a report on Wednesday, September 11th. One analyst has rated the stock with a sell rating, two have given a hold rating and nine have given a buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $45.20.

Genmab A/S Price Performance

NASDAQ GMAB traded up $0.24 on Friday, hitting $22.56. The stock had a trading volume of 1,113,174 shares, compared to its average volume of 654,423. The business's fifty day moving average price is $24.88 and its 200 day moving average price is $26.62. Genmab A/S has a 52-week low of $22.22 and a 52-week high of $32.89. The stock has a market cap of $14.93 billion, a price-to-earnings ratio of 18.64, a price-to-earnings-growth ratio of 0.67 and a beta of 0.98.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its quarterly earnings results on Thursday, August 8th. The company reported $0.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.07). The firm had revenue of $779.50 million during the quarter, compared to analysts' expectations of $734.60 million. Genmab A/S had a return on equity of 17.48% and a net margin of 29.06%. As a group, sell-side analysts anticipate that Genmab A/S will post 1.29 EPS for the current year.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.